Hyderabad Telangana, India

Pankaj Devidas Patil

This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Mylan Laboratories Limited. Active years: 2026.

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pankaj Devidas Patil: Innovator in Pharmaceutical Composition

Introduction

Pankaj Devidas Patil is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions for pain management. His innovative approach has led to the creation of a unique formulation that addresses acute pain effectively.

Latest Patents

Pankaj holds a patent for a pharmaceutical composition comprising meloxicam. This invention relates to a novel formulation designed for the treatment of acute pain. The composition includes at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof. This innovative approach enhances the efficacy of meloxicam in pain relief.

Career Highlights

Pankaj Devidas Patil is currently associated with Mylan Laboratories Limited, a leading global pharmaceutical company. His work at Mylan focuses on developing advanced pharmaceutical solutions that cater to various medical needs. His dedication to innovation in the pharmaceutical sector has positioned him as a valuable asset to his team.

Collaborations

Pankaj has collaborated with several professionals in his field, including Vivekanand Khyamgonde and Ritesh Kakaria. These collaborations have fostered a creative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Pankaj Devidas Patil's contributions to pharmaceutical innovation, particularly through his patent on meloxicam compositions, highlight his commitment to improving pain management solutions. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…